Jan 27, 2020
Pacific Neuroscience Institute Offers Final Enrollment into Important Clinical Trial for Patients with Lewy Body Dementia
Nov 07, 2019
EIP Pharma Announces U.S. FDA Grants Fast-Track Designation to Neflamapimod as a Treatment for Dementia with Lewy Bodies (DLB)
Jul 12, 2019
EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Dementia with Lewy Bodies
Jul 10, 2019
The Lewy Body Dementia Resource Center is Hosting an Exclusive Private Screening and Reception of Robin's Wish at Lincoln Center in New York
Jun 04, 2019
New Virtual Reality Immersive Learning Lab on Lewy Body Dementia with Parkinson's Disease Transforms Health Care Training and Family Caregiver Education
Mar 13, 2019
BioArctic Announces Start of Phase 1 Study of ABBV-0805 for Parkinson's Disease
Dec 14, 2018
BioArctic Outlicenses its Alpha-synuclein Antibody Portfolio for Parkinson's Disease to AbbVie After Receiving Clearance
Oct 11, 2018
ProMIS Neurosciences Identifies Novel Antibody Drug Candidates for Parkinson's Disease
Oct 02, 2018
Lewy Body Dementia is a Life-Shortening, Terminal Diagnosis
Jun 26, 2018
ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases
May 31, 2018
Second Leading Cause of Dementia Commonly Misdiagnosed
Apr 06, 2018
FAU Named A 'Research Center Of Excellence' For Lewy Body Dementia
Nov 22, 2017
Global Alpha Synuclein Market Competition by Top Manufacturers - ReportsnReports
Oct 24, 2017
Michael J. Fox Foundation and Tau Consortium Announce Partnership to Develop New Imaging Tools for Devastating Neurodegenerative Diseases
Oct 13, 2017
BioArctic's Patent for its Product Candidate Antibody BAN0805, for Parkinson's Disease, is Now Granted in Europe
Jun 19, 2017
FDA Grants Fast Track Designation to Axovant's Nelotanserin for Visual Hallucinations in Dementia with Lewy Bodies
Jun 08, 2017
New Criteria and Biomarker Tests Allow Physicians to Diagnose Dementia with Lewy Bodies in Early Stages